|
Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
|
Hitting the Target in HER2-Positive Metastatic Colorectal Cancer
STATEMENT OF NEED
An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatment... |
|
Building and Maintaining a Multidisciplinary Team for Lysosomal Disorders
This CME/CE activity with Drs. Ozlem Goker-Aplan and Walla Al-Hertani describes the importance of a multidisciplinary team approach to managing lysosomal diseases, as well as some of the challenges involved in creating and maintaining that team.
At the end of this activity, participants should be able to:
- Describe the need for a team approach to care
- Describe best practices to build a multidisciplinary team for a new patient
- Describe best practices to maintain a multidisciplinary... |
|
|
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu... |
|
|
Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC
In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!
STATEMENT OF NEED
Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite... |
|
|
Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs
STATEMENT OF NEED
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ... |
|
|
Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma
STATEMENT OF NEED
Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident... |
|
|
Putting the Freeze on Cold Agglutinin Disease
STATEMENT OF NEED
Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin i... |
|
|
Managing Patients with Rheumatic Disorders in Primary Care
Rheumatic disorders are prevalent, yet their diagnosis and treatment in affected patients are frequently challenging, contributing to a considerable disease burden. Ensuring timely intervention is critical to slow disease progression and improve patient outcomes. However, various educational gaps impede primary care clinicians from effectively achieving these goals. This 0.75-hour text-based activity features 3 modules comprised of 12 questions encountered in the primary care management of pat... |
|
|
Managing Cardiomyopathies in Lysosomal Disorders
This CME/CE activity describes the pathophysiologies and management options for lysosomal disease patients with cardiomyopathies.
At the end of this activity, participants should be able to:
- Describe the role of the cardiologist in the team approach to care
- Describe best practices to monitor cardiac symptoms in lysosomal disorders
- Describe best practices to treat cardiac symptoms in lysosomal disorders |
|
|
Acromegaly Research Highlights: ENDO 2023
This 30-minute CME-accredited program highlights the latest clinical research about acromegaly, a rare endocrine disorder. Common symptoms include subtle skeletal overgrowth; soft tissue swelling (tongue, heart, kidney, colon, and vocal cords); unusually prominent forehead and heavy brow ridge; protruding lower jaw; overbite; skin thickening; increased shoe and ring size; hypertension; increased perspiration; headaches; paresthesia; and sexual dysfunction.
There are several orphan drugs app... |
|
|
Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View
STATEMENT OF NEED
Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience immune-related adverse events, which can affect a wide variety of organ systems and can occur at any ... |
|
|
Assessing, Monitoring, and Managing Respiratory Involvement in Lysosomal Disorders
Ozlem Gore-Alpan, MD of LDRTC and John Bach, MD, Professor of Neurology at Rutgers School of Medicine discuss best practices to manage respiratory complications in persons with lysosomal disorders.
At the end of this activity, participants should be able to:
- Describe the most common LSDs that have pulmonary complications.
- Describe best practices to manage pulmonary symptoms in Pompe disease.
- Describe best practices to manage pulmonary symptoms in MPSs.
- Describe best practices to... |
|
California Dental CE Online | $99 for 25 CEs | MyDentalCE.com | Board Approved Infection Control & Dental Practice Act & Opioid Required course | 2022-24
25 CEs | $99. For California dentists including Cal OSHA Infection Control, California Dental Practice Act (both mandatory & board approved for 2023-2024), board newly approved Opioid Responsibilities, and Bloodborne Pathogens Standard Review. We also can do course substitutions & we offer group discounts. Immediately upon purchase, we send you links to the PDF course files with instructions and all the course download links. The examination links easily accessible in each course. Un... |
|
California Opioid Prescribers: Responsibilities and Requirements | Board Approved Mandated Course
On January 1, 2023, the Dental Board of California (DBC) and CA Law mandated that all Schedule II Opioid prescribers, including dentists, take a dental board approved course to fulfill the CE mandate. This brand new text-based PDF file self-instruction course is based on explicit content guidelines issued by the DBC and the Calif Code of Regulations. This 2023-2024 DBC approved course covers best practices in pain management, resources for Substance Abuse Disorder, and the regulations, respons... |
|
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Exploring Novel Treatments for Rett Syndrome
STATEMENT OF NEED
Rett syndrome is a rare, debilitating neurodevelopmental disorder almost always associated with a spontaneous mutation in the methyl-CpG-binding protein 2 (MECP2) gene on the X-chromosome. Affected individuals experience loss of purposeful hand skills, abnormalities in gait, loss of spoken language, and stereotypic hand movements, with more severe manifestations including seizures, autistic features, autonomic nervous system dysfunction, breathing abnormalities, sleep dist... |
|
|
Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy
STATEMENT OF NEED
Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to dose reductions or discontinuation of treatment. In one study, among 105 patients receiving paclitaxel for breast cancer, 36.2% needed dose reductions due to CIPN (Timmins et al, 2021). Whereas in some patients the symptoms improve with time, in others, there is progression with permanent nerve damage (Zajączkowska et al, 2019). At present, the... |
|
|
Operation Game- A Patient’s Journey Through HeFH: Diagnosis and Management
Target Audience
This activity has been designed to address the educational needs of cardiologists, cardiology nurses, lipid specialists, and primary care clinicians, including internists, pharmacists, nurses, nurse practitioners, PAs, and dietitians. It may also benefit other healthcare providers who manage patients with hypercholesterolemia.
Program Overview
Nonstatins are an essential therapy for lowering low-density lipoprotein cholesterol (LDL-C) levels in high-risk patients, such as ... |
|
|
Ace the Case: A 47-Year-Old Man With Oral Corticosteroid-Dependent Asthma
This educational activity will utilize a case study to discuss a 47-year-old man with oral corticosteroid"dependent asthma. |
|
|
Ace the Case: A 34-Year-Old Woman With Painful Swallowing
This educational activity will utilize a case study to discuss a 34-year-old woman with painful swallowing that has been progressively worsening for the past few days and is associated with anorexia, nausea, and epigastric abdominal pain. |
|
|
Ace the Case: A 62-Year-Old Woman With Unintentional Weight Loss of 20 Pounds
This educational activity will utilize a case study to discuss a 62-year-old woman with a 20-pound unintentional weight loss and recurrent emesis over the past 3 months. |
|
|
nAMD and DME Management: Rapid Response From ARVO
Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing... |
|
|
nAMD and DME Management: Rapid Response From ARVO
Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing... |
|
|
Real-World Perspectives in Managing CLL Treatment
Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ... |
|
|
Geographic Atrophy: Rapid Response from ARVO
Geographic atrophy (GA) is a pathological deterioration of the retina seen in the late stages of age-related macular degeneration (AMD). It affects 20% of people with AMD, and its prevalence increases exponentially with age. Until recently, there were no treatment options for GA, but investigation into the complement system and its role in the pathogenesis of GA has led to targeted therapies that have revolutionized the treatment paradigm. Because of the recent approval of one of these therapi... |
|
|
9th Annual Clinical Issues in Primary Care Conference
Presented by Continuing Education Company for over 30 years, our Primary Care CME Conference Series is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. Join us in May 2024 for our 9th Annual Clinical Issues in Primary Care Conference at the Fairmont Orchid, Hawaii Resort on the Big Island
Program Objectives
As a result of this conference, participants will be able to:
Assess and p... |
|
|
A Class Act in Glaucoma Management: Differentiating Rho Kinase Inhibitors From the Pack
Medical management of glaucoma primarily focuses on lowering intraocular pressure (IOP) by decreasing aqueous production, reducing episcleral venous pressure, and/or increasing uveoscleral and trabecular outflow. Recently approved agents have expanded treatment options beyond the traditional mainstays of prostaglandin analogues and β-blockers, engaging Rho kinase (ROCK) inhibition to improve outcomes for patients with glaucoma. In this CE monograph, experts in the field will review the clinic... |
|
|
Duchenne Muscular Dystrophy: Recognizing Its Earliest Signs in Infancy and Care Transition into Adulthood
Target Audience
The intended audience for this activity are neurologists, neuromuscular specialists, pediatric neurologists, genetic counselors, and pediatricians.
Program Overview
Join a panel of expert clinicians to identify the subtle and very early signs of DMD that may be detected before functional symptoms are noticed and that can help earlier diagnoses and appropriate interventions. Panelists will review the importance of matching mutations to therapeutic decisions, discuss emergin... |
|
|
Parkinson’s Disease " Updates in Diagnosis and Patient Management
Parkinson's disease is a neurodegenerative disorder, second only in prevalence to Alzheimer’s disease. Numerous therapeutic options, including carbidopa/levodopa, monoamine oxidase-B inhibitors, dopamine agonists, and device-assisted therapies, are available for treatment. These treatments are indicated at different stages following diagnosis. However, Parkinson’s disease progresses at highly variable rates, and no biomarkers, laboratory tests, or gold standard indexes are available t... |
|
|
COVID-19 Disease Behavior in Immunocompromised Patients, With Drs. Leonard Calabrese and Alfred Kim
In this podcast, expert clinicians will discuss how immune compromising conditions and iatrogenic causes of immune suppression affect risk for infection and severe outcomes with COVID-19. |
|
|
Diabetes Update 2024 - LIVE STREAMING
This highly rated Harvard Medical School CME course offers practical strategies to address the medical and systemic challenges to optimal care and updates that ensure you can deliver state-of-the-art care for your patients with diabetes.
PROGRAM HIGHLIGHTS
This program affords you the opportunity to learn from leaders in the field of diabetes who are distinguished for their outstanding teaching, knowledge, and innovations in clinical care.
Participants can rely on this program for compreh... |
|
|
The HIV Journey Staying the Course Through Critical Junctions in Care
HIV is a life-long condition that is becoming increasingly complex. Clinicians must be prepared to face myriad situations over a patient’s lifespan, relating both to their HIV and to either other comorbidities or issues such as stigma or social determinants of health. In this interactive activity, you will follow a patient diagnosed as an adolescent through his lifespan with HIV to make decisions about common challenges. Dr. Onyema Ogbuagu will review rapid ART, educating adolescents, addres... |
|
|
Hot Topics in Lupus: SLE Pathophysiology
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
|
Hot Topics in Lupus: Individualizing Steroid-Sparing Regimens
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
|
Hot Topics in Lupus: Targeted Biologic Treatment Options
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
|
Eosinophilic Esophagitis: Experts Address Your Burning Questions
Eosinophilic esophagitis (EoE) is a chronic type 2 helper (Th2)-mediated inflammatory disorder that is characterized by symptoms of esophageal dysfunction and esophageal inflammation with intraepithelial eosinophils. Once considered rare, EoE is a relatively new disease that is now commonplace and affects both children and adults. When left unmanaged, EoE can impact a patient’s ability to eat properly, leading to food impaction and increased medical expenses. Recent data indicate that many c... |
|
|
Case Challenges in nAMD and DME Management: Achieving Durable Response
The management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with intravitreal anti-vascular endothelial growth factor (VEGF) therapies has provided enhanced visual outcomes for many patients. However, the high treatment burden associated with anti-VEGF therapies can lead to lack of patient adherence, resulting in suboptimal outcomes. Personalized treatment protocols using FDA-approved agents and newer novel delivery systems, along with agents with uni... |
|
|
Parenteral Nutrition Solutions: Developing a Playbook for the Multidisciplinary Team
In these symposium highlights, a multidisciplinary panel of experts discuss a range of topics, including the role of indirect calorimetry, protein requirements, intravenous lipid emulsions, and the nutrition support team. Also highlighted are a real-world patient case and the questions and answers/panel discussion. An accompanying infographic on the importance of the nutrition support team and how to organize one can be downloaded and shared with your team. |
|
|
Optimizing Transition from Pediatric to Adult Care - LIVE STREAMING
In this special program, faculty from Harvard Medical School, the Brigham Transition Care Team, and the Boston Children’s Hospital BRIDGES Adult Transition Program provide strategies, best practices, and guidance to:
• Identify adult care providers and successfully transfer patients with rare or complex health care needs
• Assess and improve the efficacy of your current transition processes
• Tailor transition strategies to patient age, disease type, and physical/ intellectual capab... |
|
|
Sports Medicine 2024 -LIVE STREAMING
The Comprehensive 2024 Sports Medicine Update
State-of-the-Art Approaches to the Diagnosis, Treatment, Rehabilitation, and Prevention of Sports Injuries
This Harvard Medical School CME program, which is among the highest-rated HMS CME courses, provides a special and timely opportunity to hear directly from world-renowned physician specialists (physiatrists, orthopedists, radiologists), team physicians and athletic trainers for the Boston Red Sox, New England Revolution, and New England P... |
|
|
NeuroRehabilitation 2024 - LIVE STREAMING
Comprehensive Neurorehabilitation Update
Cutting-edge strategies, updates, and best practices for state-of-the-art rehabilitation
In this course, which is among the highest-rated Harvard Medical School CME courses, many of the country’s most experienced and committed neurorehabilitation experts will present cutting-edge clinical interventions, the latest findings, practical education, and hands-on methods to further your expertise in guiding your patients with stroke, SCI, TBI, brain t... |
|
|
Comprehensive Sterile Compounding
June 6th - 8th, 2024
COMPREHENSIVE STERILE COMPOUNDING is an accredited 3-day, 20-hour (2.0 CEUs) practice-based course designed for pharmacists and technicians who are experienced in compounding.
Physicians and other healthcare professionals are welcome to attend. This course will also provide initial aseptic training for pharmacists and technicians required by their state board of pharmacy to compound sterile preparations.
Participants are instructed in the proper aseptic techniques... |
|
|
Vision For Life: Maintaining Healthy Eyes in Diabetes
Program Overview
This online program is designed to help primary care clinicians who manage patients who have or are at risk for diabetic eye disease. Learn about the importance of early detection and recommended screening guidelines, how to identify patients at higher risk for diabetic eye disease, and multidisciplinary management options to help patients with diabetes preserve vision.
Learning Objectives
After completing the CME activity, learners should be better able to:
Examine th... |
|
|
Meeting Milestones in nAMD and DME Management: What's New?
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionized treatment paradigms for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, these agents are associated with a high treatment burden because of the injection frequency, and a substantial number of patients do not adhere to their treatment schedules, resulting in suboptimal response to therapy. To address these issues, new dosage regimens and surgical drug delivery approaches hav... |
|
|
WEBINAR: The GRAS is Not Always Greener: Providing Toxin-free Drug Therapy to Animal Patients
Pharmacists and pharmacy technicians often are the last line of defense in recognizing and preventing potential animal poisoning. Unfortunately, pharmacists and pharmacy technicians traditionally are trained only in human toxicology. To provide competent and confident pharmaceutical care to non-human species, pharmacists and pharmacy technicians must possess a working knowledge of species-specific susceptibilities to toxins. Factors that affect the risk of toxicity vary greatly among species; ... |
|
|
Graft vs Host Disease: Novel Management Strategies for a Chronic Condition
Target Audience
The intended audience for this activity is transplant specialists, oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with GVHD.
Program Overview
This enduring activity takes learners on a compelling journey in managing chronic graft-versus-host disease (cGVHD) by explaining the evidence-based diagnostic criteria for cGVHD for prompt diagnosis; discussing the clinical safety and efficacy data of recently approved and invest... |
|
|
Disparities in Ovarian Cancer: Increasing Awareness to Improve Risk Assessment and Outcomes
Ovarian cancer is the most common cause of cancer death in women with gynecologic malignancy and the fifth leading cause of cancer death in the US. Although the incidence of ovarian cancer is higher among White women than Black women, studies have identified disparities in assessment, care and outcomes seen among Black women with ovarian cancer. It has been shown that outcomes in clinical oncology can be improved when care is delivered by high performance teams. This activity was designed by ... |
|
|
In Case You Missed: Utilizing the Muscarinic System to Optimize Treatment Options for Schizophrenia
Schizophrenia is an incurable, neuropsychiatric disease characterized by difficulties thinking and communicating clearly as well as psychosis (ie, “positive” symptoms); difficulty functioning socially (ie, “negative” symptoms); and cognitive impairment. As many as 34% of patients with schizophrenia have treatment-resistant schizophrenia, defined as continuing symptoms despite at least 2 trials of appropriate antipsychotic treatment, and most people do not recover from it. Patients with... |
|
|
28th Annual Hypertension, Diabetes & Dyslipidemia Conference
This three day intensive conference, held on June 19-21, 2024 in Charleston, South Carolina, addresses all the issues confronting clinicians who treat challenging patients with diabetes, hypertension, and dyslipidemia and how to apply this knowledge to everyday practice.
Over the past several years controversies in the appropriate target for Hemoglobin A1C, BP, and LDL-Cholesterol on outcome improvement continue to occur in Type 2 diabetes, Hypertension, and Dyslipidemia, respectively. Desp... |
|